Aura Biosciences, Inc.
AURA
$7.64
-$0.01-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 202.22% | 21.33% | -2.43% | -7.55% | -2.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.00% | 20.08% | -2.05% | 20.12% | 25.71% |
| Operating Income | -68.00% | -20.08% | 2.05% | -20.12% | -25.71% |
| Income Before Tax | -69.10% | -22.61% | 1.03% | -24.31% | -32.62% |
| Income Tax Expenses | -39.58% | -38.89% | -37.50% | -39.53% | -- |
| Earnings from Continuing Operations | -68.91% | -22.57% | 1.06% | -24.18% | -32.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.91% | -22.57% | 1.06% | -24.18% | -32.86% |
| EBIT | -68.00% | -20.08% | 2.05% | -20.12% | -25.71% |
| EBITDA | -68.78% | -20.35% | 2.00% | -20.54% | -26.18% |
| EPS Basic | -3.31% | 8.92% | 26.37% | 6.47% | -13.47% |
| Normalized Basic EPS | -3.41% | 8.88% | 26.35% | 6.39% | -13.29% |
| EPS Diluted | -3.31% | 8.92% | 26.37% | 6.47% | -13.47% |
| Normalized Diluted EPS | -3.41% | 8.88% | 26.35% | 6.39% | -13.29% |
| Average Basic Shares Outstanding | 63.51% | 34.56% | 34.37% | 32.77% | 17.09% |
| Average Diluted Shares Outstanding | 63.51% | 34.56% | 34.37% | 32.77% | 17.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |